

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

Assignment ID: PATI669885

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
Viracta Therapeutics, Inc.	12/03/2024
RECEIVING PARTY DATA	
Company Name:	Xoma (US) LLC
Street Address:	2200 Powell Street, Suite 310
City:	Emeryville
State/Country:	CALIFORNIA
Postal Code:	94608
PROPERTY NUMBERS Total: 6	
Property Type	Number
Application Number:	60947291
Patent Number:	8293752
Patent Number:	8802657
Patent Number:	9556177
Patent Number:	9920048
PCT Number:	US0868762
CORRESPONDENCE DATA	
Fax Number:	9494754754
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(949)451-3800
Email:	skann@gibsondunn.com
Correspondent Name:	Stephanie Kann
Address Line 1:	3161 Michelson Drive
Address Line 2:	Gibson, Dunn & Crutcher LLP
Address Line 4:	Irvine, CALIFORNIA 92612-4412
ATTORNEY DOCKET NUMBER:	98176-00030
NAME OF SUBMITTER:	STEPHANIE KANN
SIGNATURE:	STEPHANIE KANN
DATE SIGNED:	12/03/2024

Total Attachments: 14

source=Viracta-XOMA IP Assignment Agreement (Executed)#page1.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page2.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page3.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page4.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page5.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page6.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page7.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page8.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page9.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page10.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page11.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page12.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page13.tiff
source=Viracta-XOMA IP Assignment Agreement (Executed)#page14.tiff

INTELLECTUAL PROPERTY ASSIGNMENT

This INTELLECTUAL PROPERTY ASSIGNMENT (this “**Assignment**”) is made and entered into as of December 3, 2024 (the “**Assignment Effective Date**”) by and between VIRACTA THERAPEUTICS, INC., a corporation organized and existing under the laws of Delaware, with an office located at 2533 South Coast Highway 101, #210, Cardiff, CA 92007 (“**Assignor**”), and XOMA (US) LLC, a Delaware limited liability company with its principal place of business at 2200 Powell Street, Suite 310, Emeryville, California 94608 (“**Assignee**”). Assignor and Assignee are individually referred to herein as a “**Party**,” and collectively as the “**Parties**.” Capitalized terms used herein without definition shall have the meanings assigned to such terms in the License Agreement (defined below).

WHEREAS, Assignor (successor in interest to Sunesis Pharmaceuticals, Inc.) and Day One Biopharmaceuticals, Inc., successor in interest to DOT Therapeutics-1, Inc. (“**Day One**”) entered into that certain License Agreement For RAF, effective as of December 16, 2019, as amended by that certain Amendment No. 1 to License Agreement for RAF dated March 4, 2024, as may be further amended, modified or supplemented from time to time (the “**License Agreement**”);

WHEREAS, Assignor, Assignee and Viracta Royalty Fund, LLC entered into that certain Royalty Purchase Agreement dated March 22, 2021, as supplemented by that certain Letter Agreement dated March 22, 2021, as amended by that certain Joinder and Amendment to Royalty Purchase Agreement dated March 22, 2021, as amended by that certain Amendment No. 1 to Royalty Purchase Agreement for Raf dated March 4, 2024 (the “**Purchase Agreement Amendment**”), as may be further amended, modified or supplemented from time to time (the “**Purchase Agreement**”), which provides for, among other things, a sale of certain royalty payments payable to Assignor under the License Agreement to Assignee;

WHEREAS, under Section 2 of the Purchase Agreement Amendment, Assignor agreed to use commercially reasonable efforts to assign, and Assignor is now assigning, all of its right, title and interest in and to the License Agreement to Assignee pursuant to that certain Assignment and Novation Agreement, dated as of the Assignment Effective Date, by and among Assignor, Assignee, and Day One as may be amended, modified or supplemented from time to time (the “**License Agreement Assignment**”);

WHEREAS, in connection with such assignment, the Parties desire that Assignor transfer to Assignee all of the right, title and interest of Assignor in and to the Assigned IP; and

WHEREAS, Assignee wishes to acquire all of Assignor’s right, title and interest in and to the Assigned IP, and Assignor wishes to assign such right, title and interest in and to such Assigned IP to Assignee.

NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

1. Transfer of Assigned IP. Assignor does hereby irrevocably sell, transfer, convey, assign and deliver to Assignee and its successors and assigns, and Assignee does hereby

unconditionally accept: (a) all of Assignor's right, title and interest in and to the Sunesis Licensed Technology, including any such Sunesis Licensed Technology set forth on Exhibit A attached hereto (collectively, the "**Assigned IP**"); (b) all licenses, covenants not to sue, and similar contractual rights or permissions, whether exclusive or nonexclusive, to the extent such licenses, covenants, rights or permissions are (i) granted in respect of any of the Assigned IP and (ii) sublicensable or assignable, (c) all royalties, fees, income, payments, and other proceeds now or hereafter due or payable to the Assignor with respect to any of the foregoing; (d) all claims, causes of action and enforcement rights, whether currently pending, filed, or otherwise, with respect to the Assigned IP, including all rights to damages, injunctive relief and other remedies for past, current and future infringement of the Assigned IP; and (e) all other rights, privileges, protections, covenants, obligations and liabilities of any kind whatsoever of Assignor arising as or of after the date hereof accruing under any of the foregoing.

2. Transfer of Know-How. Promptly following the Assignment Effective Date (and in any event within 10 days following the Assignment Effective Date), Assignor will deliver to Assignee, at Assignor's reasonable cost and expense, all existing Know-How in Assignor's possession (if any) (the "**Assigned Know-How**") under the Sunesis Licensed Technology, including all Sunesis Licensed Know-How in existence as of the Assignment Effective Date, by a method reasonably acceptable to Assignee. For a period of 40 days from the date that Assignee receives the Assigned Know-How, Assignor shall make its employees available to Assignee to answer any questions or provide instruction or otherwise assist Assignee with such transfer.

3. Follow-up Requests. In the event that after the Assignment Effective Date, Assignee or Assignor discovers or learns of any Know-How that was inadvertently omitted from, but reasonably should have been included in the Assigned Know-How or in Exhibit A, Assignor (a) hereby assigns, transfers and conveys and agrees to assign, transfer and convey to and (b) agrees to promptly deliver to, Assignee such Know-How in the manner specified in Section 2 (Transfer of Know-How).

4. Maintenance, Prosecution, and Enforcement. After the Assignment Effective Date, Assignee shall assume from Assignor any responsibility for the preparation, filing, prosecution and maintenance, enforcement and defense of any Assigned IP that constitutes Patent Rights for which Assignor was responsible under the License Agreement (if any), whether as the initial controlling party or pursuant to its right of assumption of such control. Upon Assignee's request, Assignor shall reasonably cooperate in transferring to Assignee any of Assignor's responsibility for the preparation, filing, prosecution and maintenance, enforcement and defense of such Patent Rights, and shall provide Assignee with copies, at Assignor's expense, of any requested documents in its or its Affiliates' possession relating thereto (if any).

5. Further Assurances. Assignor covenants and agrees that, at any time and from time to time upon the request of Assignee, at Assignee's expense, Assignor shall provide any further necessary documentation and do all further acts reasonably requested by Assignee to confirm and perfect title in and to the Assigned IP in Assignee, its successors and assigns. Assignor hereby authorizes the Commissioner for Patents and any other governmental authority to record and register this Assignment upon request by Assignee. The Assignor and Assignee shall execute and deliver such further instruments and take such other action as may be necessary or advisable or is reasonably requested by the other party to make effective the transactions contemplated hereby.

Without limiting the Parties' rights and obligations under Section 3 (Follow-up Requests), the Parties may amend the Exhibits hereto by mutual agreement to include any additional intellectual property assets in such Exhibits.

6. Entire Agreement. This Assignment and the License Agreement Assignment (including the schedules thereto, if any) reflect the entire understanding of the Parties relating to the sale, assignment, transfer, conveyance and delivery of the Assigned IP from Assignor to Assignee, and supersede all prior or contemporaneous agreements, understandings, negotiations, communications, discussions, or letters of intent between or among the Parties regarding the subject matter of this Assignment and the License Agreement Assignment. This Assignment may be amended or modified only with the prior written consent of the Parties.

7. Successors and Assigns. This Assignment shall be binding upon and inure to the benefit of the Parties and their respective successors and assigns.

8. Governing Law and Venue.

(a) This Assignment shall be governed by and construed in accordance with the internal laws of the State of Delaware without giving effect to the conflict of law provisions thereof to the extent such provisions would require or permit the application of the laws of any jurisdiction other than the State of Delaware.

(b) Any unresolved controversy or dispute arising out of or relating to this Assignment shall be submitted to arbitration by one arbitrator mutually agreed upon by the Parties, and if no such agreement can be reached within 30 days after the bringing of the applicable action, by one arbitrator chosen by the American Arbitration Association (the "AAA") having reasonable experience in the transactions of the type provided for in this Assignment. The arbitration shall take place in San Francisco, California, in accordance with the AAA rules then in effect, and judgment upon any award rendered in such arbitration will be binding and may be entered in any court having jurisdiction thereof. There shall be limited discovery prior to the arbitration hearing as follows: (i) exchange of witness lists and copies of documentary evidence and documents relating to or arising out of the issues to be arbitrated, (ii) depositions of all party witnesses, and (iii) such other depositions as may be allowed by the arbitrators upon a showing of good cause. Depositions shall be conducted in accordance with the California Civil Practice Law and Rules, the arbitrator shall be required to provide in writing to the Parties the basis for the award or order of such arbitrator, and a court reporter shall record all hearings, with such record constituting the official transcript of such proceedings.

(c) Each Party will bear its own costs in respect of any disputes arising under this Assignment. Each of the Parties consents to personal jurisdiction for any equitable action sought in the U.S. District Court of the Northern District of California or any court of the State of California having subject matter jurisdiction.

9. Severability. If any provision of this Assignment or the application of any such provision to any person or circumstance shall be declared by any court of competent jurisdiction to be invalid, illegal, void or unenforceable in any respect, all other provisions of this Assignment,

or the application of such provisions to persons or circumstances other than those as to which it has been held invalid, illegal, void or unenforceable, shall nevertheless remain in full force and effect and shall in no way be affected, impaired or invalidated thereby. Upon such determination that any provisions, or the application of any such provision, is invalid, illegal, void or unenforceable, the Parties shall negotiate in good faith to modify this Assignment so as to effect the original intent of the Parties as closely as possible to the fullest extent permitted by applicable law in an acceptable manner to the end that the transactions contemplated hereby are fulfilled to the greatest extent possible.

10. Counterparts. This Assignment may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Assignment delivered by facsimile, email or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.

11. Headings. The section headings hereof have been inserted for convenience of reference only and shall not be construed to affect the meaning, construction or effect of this Assignment.

12. License Agreement Assignment Shall Control. Nothing in this Assignment shall change, amend, limit, extend or alter (nor shall it be deemed or construed as changing, amending, extending or altering) the terms or conditions of the License Agreement Assignment or any right, liability or obligation of the Assignor or Assignee arising under the License Agreement Assignment. In the event that any of the provisions of this Assignment are determined to conflict with the terms of the License Agreement Assignment, the terms of the License Agreement Assignment shall control.

Remainder of page intentionally left blank.

IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed by their duly authorized representatives as of the Assignment Effective Date.

ASSIGNOR:

VIRACTA THERAPEUTICS, INC.

By: Michael Faerm

Name: Michael Faerm

Title: Chief Financial Officer

CERTIFICATE OF ACKNOWLEDGEMENT

STATE OF _____

SS:

COUNTY OF _____

On this _____ day of _____ before me, the undersigned, personally appeared _____, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to within the instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person on behalf of whom the individual acted, executed the instrument.

Notary Signature and Seal

PLEASE SEE ATTACHED
CALIFORNIA

☐ JURAT

☒ ACKNOWLEDGMENT

ACKNOWLEDGMENT

A notary public or other officer completing this certificate verifies only the identity of the individual who signed the document to which this certificate is attached, and not the truthfulness, accuracy, or validity of that document.

State of California
County of San Diego


On DEC. 03, 2024 before me, JAE H LEE, A Notary Public
(insert name and title of the officer)

personally appeared MICHAEL FAERM
who proved to me on the basis of satisfactory evidence to be the person(s) whose name(s) is/are subscribed to the within instrument and acknowledged to me that he/she/they executed the same in his/her/their authorized capacity(ies), and that by his/her/their signature(s) on the instrument the person(s), or the entity upon behalf of which the person(s) acted, executed the instrument.

I certify under PENALTY OF PERJURY under the laws of the State of California that the foregoing paragraph is true and correct.

WITNESS my hand and official seal.

Signature Lee, J. H. (Seal)




IN WITNESS WHEREOF, the Parties have caused this Assignment to be executed
by their duly authorized representatives as of the Assignment Effective Date.

ASSIGNEE:

XOMA (US) LLC

By:



Name: Thomas Burns

Title: Chief Financial Officer

CERTIFICATE OF ACKNOWLEDGEMENT

STATE OF


CA

SS:

COUNTY OF

Marin

On this 3rd day of December, 2021 before me, the undersigned, personally appeared Thomas Macgille Burns, personally known to me or proved to me on the basis of satisfactory evidence to be the individual whose name is subscribed to within the instrument and acknowledged to me that he/she executed the same in his/her capacity, and that by his/her signature on the instrument, the individual, or the person on behalf of whom the individual acted, executed the instrument.



Tom Royall
Notary Signature and Seal

Exhibit A

Assigned IP

WSGR Ref. No.	Country	Type	Application Number	Filing Date	Pub. Number	Pub. Date	Patent Number	Issue Date	Title	Status
57841-701.101	United States of America	PRO	60/947,291	06/29/07					COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Expired
57841-701.201	United States of America	ORD	12/164,762	06/30/08	US 2009-0036419 A1	02/05/09	8,293,752	10/23/12	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.301	United States of America	CON	13/657,506	10/22/12	US 2013-0065858 A1	03/14/13	8,802,657	08/12/14	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.401	United States of America	DIV	14/444,007	07/28/14	US 2015-0080568 A1	03/19/15	9,556,177	01/31/17	SUBSTITUTED 1,3-THIAZOLES AS SYNTHETIC INTERMEDIATES FOR PREPARATION OF RAF KINASE INHIBITORS	Granted
57841-701.402	United States of America	DIV	15/380,515	12/15/16	US 2017-0158686 A1	06/08/17	9,920,048	03/20/18	SUBSTITUTED PYRIMIDINES FOR INHIBITING RAF KINASE ACTIVITY	Granted
57841-701.601	PCT	ORD	PCT/US2008/068762	06/30/08	WO 2009/006389	01/08/09			PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Nationalized
57841-701.611	European Patent Conventio	PCT	8772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6111	European Patent Conventio	DIV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.621	Germany	EPP	08772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6211	Germany	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.631	France	EPP	08772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6311	France	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.641	United Kingdom	EPP	08772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6411	United Kingdom	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted

WSGR Ref. No.	Country	Type	Application Number	Filing Date	Pub. Number	Pub. Date	Patent Number	Issue Date	Title	Status
57841-701.6511	Belgium	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.653	Switzerland	EPP	08772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6531	Switzerland	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.6561	Denmark	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.658	Spain	EPP	08772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6581	Spain	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.6621	Ireland	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.663	Italy	EPP	08772238.5	06/30/08	2167489	03/31/10	2167489	05/03/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6631	Italy	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.6661	Netherlands	EDV	17168722.1	06/30/08	3231798	10/18/17	3231798	10/09/19	COMPOUNDS FOR PREPARING RAF KINASE INHIBITORS	Granted
57841-701.681	Australia	PCT	2008273002	06/30/08	200827300	01/08/09	20082730	05/08/14	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.6811	Australia	DIV	2014200030	01/03/14					PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.691	Brazil	PCT	PI0813499-5	06/30/08	PI0813499-5	01/06/15	PI081349		COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.701	Canada	PCT	2,693,182	06/30/08	2,693,182	01/08/09	2,693,182	01/02/18	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.711	China (People's Republic)	PCT	200860022788.9	06/30/08	101784545	07/21/10	ZL200880	04/20/16	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.7111	China (People's Republic)	DIV	201410466320.6	06/30/08	CN1043708	02/25/15	ZL201410	01/18/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.7112	China (People's Republic)	DIV	201611139456.1	06/30/08	CN1069573	07/18/17	10695731	12/31/19	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted

WSGR Ref. No.	Country	Type	Application Number	Filing Date	Pub. Number	Pub. Date	Patent Number	Issue Date	Title	Status
57841-701.731	Israel	PCT	202835	06/30/08		12/31/14	202835	04/01/15	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.741	India	PCT	613/DELNP/2010	06/30/08			279878	01/31/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.7411	India	DIV	201618002112	06/30/08	IN201618002112A	08/12/16	376855	09/09/21	A METHOD FOR PREPARING A COMPOUND OF FORMULA II-A	Granted
57841-701.761	Japan	PCT	2010-515219	06/30/08			5649445	11/21/14	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.7611	Japan	DIV	2013-195277	06/30/08			5962622	07/08/16	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.7612	Japan	DIV	2015-43208	03/05/15					COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	WITHDREW
57841-701.771	Korea, Republic of	PCT	10-2009-7027037	06/30/08	2010-003384	03/29/10	10-1650140	08/16/16	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.7711	Korea, Republic of	DIV	10-2016-7004471	06/30/08	KR 20160027992	03/10/16	10-1764076	07/26/17	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.781	Mexico	PCT	MX/a/2009/014276	06/30/08			319319	04/11/14	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.791	New Zealand	PCT	582352	06/30/08	582352	06/29/12	582352	10/08/12	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.801	Philippines	PCT	12010500014	06/30/08			12010500014	06/04/14	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.811	Russian Federation	PCT	2009149214	06/30/08			2492166	09/10/13	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.821	Singapore	PCT	2009086331	06/30/08			157900	10/31/12	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.841	South Africa	PCT	2009/09223	06/30/08			2009/09223	05/28/14	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.851	Taiwan	ORD	097124450	06/27/08	200916467	04/16/09	1444379	07/11/14	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.871	Argentina	ORD	P080102801	06/27/08	AR 067354 A1	10/07/09	AR067354 B1	02/27/18	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.881	Chile	ORD	01933-2008	06/27/08	2008001933	09/25/09	50582	01/14/15	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Abandoned

PATENT

REEL: 069474 FRAME: 0063

WSGR Ref. No.	Country	Type	Application Number	Filing Date	Pub. Number	Pub. Date	Patent Number	Issue Date	Title	Status
57841-701.891	Hong Kong	REP	10107335.7	08/02/10			HK1143357	05/04/18	PYRIMIDINE DERIVATIVES USEFUL AS RAF KINASE INHIBITORS	Granted
57841-701.921	Indonesia	PCT	W00200903699	06/30/08			IDP000047584	09/07/17	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.930	Ukraine	PCT	20090013589	06/30/08			101478	04/10/13	COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Abandoned
57841-701.9660	Gulf Cooperation Council	ORD	11195	06/27/08			GC0009442	12/31/18	COMPOUNDS USEFUL AS RAF	Abandoned
57841-701.9770	Venezuela	ORD	2008-001277	06/30/08					COMPOUNDS USEFUL AS RAF KINASE INHIBITORS	Abandoned

PATENT

REEL: 069474 FRAME: 0064

RECORDED: 12/03/2024